• 48-week Phase III data showed Cyltezo^® and Humira^® have similar efficacy, safety and immunogenicity in people with rheumatoid arthritis¹
• Patients who switched at week 24 from Humira^® to Cyltezo^® showed no difference to continuous Humira^® usage¹
• Data will be presented at the American College of Rheumatology / Association of Rheumatology Health Professionals Annual Meeting

INGELHEIM, Germany -- (BUSINESS WIRE) --

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo^® (adalimumab-adbm) and reference product Humira^®*. The 48-week data showed that Cyltezo^® is equivalent, with no clinically meaningful differences in efficacy, safety and immunogenicity to Humira^® in people with moderately-to-severely active rheumatoid arthritis (RA), including in patients who switched from Humira^® to Cyltezo^® at week 24.¹

“These data are an important addition to the robust body of evidence demonstrating Cyltezo^® is biosimilar to Humira^®,” said Karsten Kissel, MD, Head of Global Medical Affairs Biosimilars at Boehringer Ingelheim. “Biosimilars have potential cost benefits to the healthcare system and support affordable access to important biologic medicines for patients living with chronic inflammatory diseases like RA.”

“In addition to the 48-week efficacy results, the adalimumab biosimilar Cyltezo^® showed equivalent safety and immunogenicity to Humira^®,” said Stanley B. Cohen, MD, Metroplex Clinical Research Center, Presbyterian Hospital, Dallas, Texas. “Consistent results were also demonstrated when patients were switched to Cyltezo^® from the reference product.”

These data will be presented at the American College of Rheumatology / Association of Rheumatology Health Professionals Annual Meeting in San Diego, California.

In the EU, Cyltezo^® recently received positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for multiple chronic inflammatory diseases including, in adults:

• Moderate to severely active rheumatoid arthritis
• Psoriatic arthritis
• Moderate to severely active Crohn's disease
• Severe active ankylosing spondylitis
• Moderate to severely active ulcerative colitis
• Severe axial spondyloarthritis without radiographic evidence of AS
• Moderate to severe chronic plaque psoriasis
• Moderate to severe hidradenitis suppurativa
• Non-infectious intermediate, posterior and panuveitis.

The CHMP also recommended approval of Cyltezo^® for the treatment of paediatric inflammatory diseases, including moderate to severe Crohn's disease (age six and older), severe chronic plaque psoriasis (age four and older), enthesitis-related arthritis (age six and older) and polyarticular juvenile idiopathic arthritis (age two and older).

Cyltezo^® is not commercially available in Europe or the U.S. at this time. In any event Boehringer Ingelheim does not intend to launch Cyltezo^® in the EU before expiration of the respective SPC for adalimumab in October 2018. Boehringer Ingelheim is currently engaged in patent litigation with AbbVie in the U.S.

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

For references and notes to editors, please visit : http://www.boehringer-ingelheim.com/press-release/one-year-data-showing-cyltezo-equivalent-humira

View source version on businesswire.com: http://www.businesswire.com/news/home/20171106005757/en/

CONTACT:

Media Contact
Boehringer Ingelheim
Corporate Communications
Media + PR
Dr. Julia Knebel
Phone: +49 6132 – 77 95614
Fax: +49 6132 – 77 6601
Email: press@boehringer-ingelheim.com
www.boehringer-ingelheim.com